| |
| U S |
|
 55.4 % |
of total Revenue |
| International |
|
44.6 % |
of total Revenue |
| Innovative Medicine |
|
64.11 % |
of total Revenue |
| Innovative Medicine U S |
|
36.87 % |
of total Revenue |
| Innovative Medicine International |
|
27.24 % |
of total Revenue |
| Innovative Medicine Oncology |
|
28.98 % |
of total Revenue |
| Innovative Medicine Oncology U S |
|
15.02 % |
of total Revenue |
| Innovative Medicine Oncology International |
|
13.96 % |
of total Revenue |
| Innovative Medicine Oncology DARZALEX |
|
16.47 % |
of total Revenue |
| Innovative Medicine Oncology DARZALEX U S |
|
9.18 % |
of total Revenue |
| Innovative Medicine Oncology DARZALEX International |
|
7.3 % |
of total Revenue |
| Innovative Medicine Oncology CARVYKTI |
|
2.48 % |
of total Revenue |
| Innovative Medicine Oncology CARVYKTI U S |
|
1.8 % |
of total Revenue |
| Innovative Medicine Oncology CARVYKTI International |
|
0.68 % |
of total Revenue |
| Innovative Medicine Oncology Tecvayli |
|
0.84 % |
of total Revenue |
| Innovative Medicine Oncology Tecvayli U S |
|
0.53 % |
of total Revenue |
| Innovative Medicine Oncology Tecvayli International |
|
0.31 % |
of total Revenue |
| Innovative Medicine Oncology TALVEY |
|
0.63 % |
of total Revenue |
| Innovative Medicine Oncology TALVEY U S |
|
0.42 % |
of total Revenue |
| Innovative Medicine Oncology TALVEY International |
|
0.21 % |
of total Revenue |
| Innovative Medicine Oncology RYBREVANT LAZCLUZE |
|
1.07 % |
of total Revenue |
| Innovative Medicine Oncology RYBREVANT LAZCLUZE U S |
|
0.73 % |
of total Revenue |
| Innovative Medicine Oncology RYBREVANT LAZCLUZE International |
|
0.34 % |
of total Revenue |
| Innovative Medicine Oncology ERLEADA |
|
3.94 % |
of total Revenue |
| Innovative Medicine Oncology ERLEADA U S |
|
1.42 % |
of total Revenue |
| Innovative Medicine Oncology ERLEADA International |
|
2.52 % |
of total Revenue |
| Innovative Medicine Oncology IMBRUVICA |
|
2.74 % |
of total Revenue |
| Innovative Medicine Oncology IMBRUVICA U S |
|
0.59 % |
of total Revenue |
| Innovative Medicine Oncology IMBRUVICA International |
|
2.15 % |
of total Revenue |
| Innovative Medicine Oncology Other Oncology |
|
0.8 % |
of total Revenue |
| Innovative Medicine Oncology Other Oncology U S |
|
0.35 % |
of total Revenue |
| Innovative Medicine Oncology Other Oncology International |
|
0.44 % |
of total Revenue |
| Innovative Medicine Immunology |
|
14.05 % |
of total Revenue |
| Innovative Medicine Immunology U S |
|
7.71 % |
of total Revenue |
| Innovative Medicine Immunology International |
|
6.33 % |
of total Revenue |
| Innovative Medicine Immunology Tremfya |
|
6.68 % |
of total Revenue |
| Innovative Medicine Immunology Tremfya U S |
|
4.33 % |
of total Revenue |
| Innovative Medicine Immunology Tremfya International |
|
2.35 % |
of total Revenue |
| Innovative Medicine Immunology SIMPONI SIMPONI ARIA |
|
2.69 % |
of total Revenue |
| Innovative Medicine Immunology SIMPONI SIMPONI ARIA U S |
|
1.12 % |
of total Revenue |
| Innovative Medicine Immunology SIMPONI SIMPONI ARIA International |
|
1.57 % |
of total Revenue |
| Innovative Medicine Immunology Remicade |
|
1.75 % |
of total Revenue |
| Innovative Medicine Immunology Remicade U S |
|
1.12 % |
of total Revenue |
| Innovative Medicine Immunology Remicade International |
|
0.57 % |
of total Revenue |
| Innovative Medicine Immunology STELARA |
|
2.73 % |
of total Revenue |
| Innovative Medicine Immunology STELARA U S |
|
0.91 % |
of total Revenue |
| Innovative Medicine Immunology STELARA International |
|
1.81 % |
of total Revenue |
| Innovative Medicine Immunology OTHER IMMUNOLOGY |
|
0.19 % |
of total Revenue |
| Innovative Medicine Immunology OTHER IMMUNOLOGY U S |
|
0.16 % |
of total Revenue |
| Innovative Medicine Immunology OTHER IMMUNOLOGY International |
|
0.04 % |
of total Revenue |
| Innovative Medicine Infectious Diseases |
|
3.69 % |
of total Revenue |
| Innovative Medicine Infectious Diseases U S |
|
1.42 % |
of total Revenue |
| Innovative Medicine Infectious Diseases International |
|
2.27 % |
of total Revenue |
| Innovative Medicine Infectious Diseases EDURANT rilpivirine |
|
1.7 % |
of total Revenue |
| Innovative Medicine Infectious Diseases EDURANT rilpivirine U S |
|
0.03 % |
of total Revenue |
| Innovative Medicine Infectious Diseases EDURANT rilpivirine International |
|
1.67 % |
of total Revenue |
| Innovative Medicine Infectious Diseases PREZISTA PREZCOBIX REZOLSTA SYMTUZA |
|
1.84 % |
of total Revenue |
| Innovative Medicine Infectious Diseases PREZISTA PREZCOBIX REZOLSTA SYMTUZA U S |
|
1.39 % |
of total Revenue |
| Innovative Medicine Infectious Diseases PREZISTA PREZCOBIX REZOLSTA SYMTUZA International |
|
0.45 % |
of total Revenue |
| Innovative Medicine Infectious Diseases OTHER INFECTIOUS DISEASES |
|
0.15 % |
of total Revenue |
| Innovative Medicine Infectious Diseases OTHER INFECTIOUS DISEASES U S |
|
0 % |
of total Revenue |
| Innovative Medicine Infectious Diseases OTHER INFECTIOUS DISEASES International |
|
0.15 % |
of total Revenue |
| Innovative Medicine Neuroscience |
|
9.04 % |
of total Revenue |
| Innovative Medicine Neuroscience U S |
|
6.21 % |
of total Revenue |
| Innovative Medicine Neuroscience International |
|
2.83 % |
of total Revenue |
| Innovative Medicine Neuroscience SPRAVATO |
|
1.94 % |
of total Revenue |
| Innovative Medicine Neuroscience SPRAVATO U S |
|
1.69 % |
of total Revenue |
| Innovative Medicine Neuroscience SPRAVATO International |
|
0.25 % |
of total Revenue |
| Innovative Medicine Neuroscience CAPLYTA |
|
1.12 % |
of total Revenue |
| Innovative Medicine Neuroscience CAPLYTA U S |
|
1.12 % |
of total Revenue |
| Innovative Medicine Neuroscience INVEGA SUSTENNA XEPLION INVEGA TRINZA TREVICTA |
|
4.31 % |
of total Revenue |
| Innovative Medicine Neuroscience INVEGA SUSTENNA XEPLION INVEGA TRINZA TREVICTA U S |
|
3.15 % |
of total Revenue |
| Innovative Medicine Neuroscience INVEGA SUSTENNA XEPLION INVEGA TRINZA TREVICTA International |
|
1.16 % |
of total Revenue |
| Innovative Medicine Neuroscience CONCERTA Methylphenidate |
|
0.57 % |
of total Revenue |
| Innovative Medicine Neuroscience CONCERTA Methylphenidate U S |
|
0.09 % |
of total Revenue |
| Innovative Medicine Neuroscience CONCERTA Methylphenidate International |
|
0.48 % |
of total Revenue |
| Innovative Medicine Neuroscience OTHER NEUROSCIENCE |
|
1.09 % |
of total Revenue |
| Innovative Medicine Neuroscience OTHER NEUROSCIENCE U S |
|
0.16 % |
of total Revenue |
| Innovative Medicine Neuroscience OTHER NEUROSCIENCE International |
|
0.93 % |
of total Revenue |
| Innovative Medicine Pulmonary Hypertension |
|
4.72 % |
of total Revenue |
| Innovative Medicine Pulmonary Hypertension U S |
|
3.45 % |
of total Revenue |
| Innovative Medicine Pulmonary Hypertension International |
|
1.26 % |
of total Revenue |
| Innovative Medicine Pulmonary Hypertension UPTRAVI |
|
2.01 % |
of total Revenue |
| Innovative Medicine Pulmonary Hypertension UPTRAVI U S |
|
1.6 % |
of total Revenue |
| Innovative Medicine Pulmonary Hypertension UPTRAVI International |
|
0.41 % |
of total Revenue |
| Innovative Medicine Pulmonary Hypertension OPSUMIT OPSYNVI |
|
2.52 % |
of total Revenue |
| Innovative Medicine Pulmonary Hypertension OPSUMIT OPSYNVI U S |
|
1.8 % |
of total Revenue |
| Innovative Medicine Pulmonary Hypertension OPSUMIT OPSYNVI International |
|
0.71 % |
of total Revenue |
| Innovative Medicine Pulmonary Hypertension Other |
|
0.19 % |
of total Revenue |
| Innovative Medicine Pulmonary Hypertension Other U S |
|
0.05 % |
of total Revenue |
| Innovative Medicine Pulmonary Hypertension Other International |
|
0.14 % |
of total Revenue |
| Innovative Medicine Cardiovascular Metabolism Other |
|
3.64 % |
of total Revenue |
| Innovative Medicine Cardiovascular Metabolism Other U S |
|
3.05 % |
of total Revenue |
| Innovative Medicine Cardiovascular Metabolism Other International |
|
0.59 % |
of total Revenue |
| Innovative Medicine Cardiovascular Metabolism Other Other |
|
0.97 % |
of total Revenue |
| Innovative Medicine Cardiovascular Metabolism Other Other U S |
|
0.38 % |
of total Revenue |
| Innovative Medicine Cardiovascular Metabolism Other Other International |
|
0.59 % |
of total Revenue |
| Innovative Medicine Cardiovascular Metabolism Other XARELTO |
|
2.67 % |
of total Revenue |
| Innovative Medicine Cardiovascular Metabolism Other XARELTO U S |
|
2.67 % |
of total Revenue |
| Innovative Medicine Total PH ID CVM Other |
|
12.05 % |
of total Revenue |
| Innovative Medicine Total PH ID CVM Other U S |
|
7.93 % |
of total Revenue |
| Innovative Medicine Total PH ID CVM Other International |
|
4.13 % |
of total Revenue |
| MEDTECH |
|
35.89 % |
of total Revenue |
| MEDTECH U S |
|
18.53 % |
of total Revenue |
| MEDTECH International |
|
17.36 % |
of total Revenue |
| MEDTECH Cardiovascular |
|
9.88 % |
of total Revenue |
| MEDTECH Cardiovascular U S |
|
5.81 % |
of total Revenue |
| MEDTECH Cardiovascular International |
|
4.06 % |
of total Revenue |
| MEDTECH ELECTROPHYSIOLOGY |
|
6.19 % |
of total Revenue |
| MEDTECH ELECTROPHYSIOLOGY U S |
|
3.06 % |
of total Revenue |
| MEDTECH ELECTROPHYSIOLOGY International |
|
3.13 % |
of total Revenue |
| MEDTECH ABIOMED |
|
2.03 % |
of total Revenue |
| MEDTECH ABIOMED U S |
|
1.62 % |
of total Revenue |
| MEDTECH ABIOMED International |
|
0.42 % |
of total Revenue |
| MEDTECH Shockwave |
|
1.27 % |
of total Revenue |
| MEDTECH Shockwave U S |
|
1.01 % |
of total Revenue |
| MEDTECH Shockwave International |
|
0.26 % |
of total Revenue |
| MEDTECH Other Cardiovascular |
|
0.39 % |
of total Revenue |
| MEDTECH Other Cardiovascular U S |
|
0.13 % |
of total Revenue |
| MEDTECH Other Cardiovascular International |
|
0.26 % |
of total Revenue |
| MEDTECH Orthopaedics |
|
9.9 % |
of total Revenue |
| MEDTECH Orthopaedics U S |
|
5.96 % |
of total Revenue |
| MEDTECH Orthopaedics International |
|
3.94 % |
of total Revenue |
| MEDTECH Orthopaedics HIPS |
|
1.81 % |
of total Revenue |
| MEDTECH Orthopaedics HIPS U S |
|
1.15 % |
of total Revenue |
| MEDTECH Orthopaedics HIPS International |
|
0.66 % |
of total Revenue |
| MEDTECH Orthopaedics KNEES |
|
1.75 % |
of total Revenue |
| MEDTECH Orthopaedics KNEES U S |
|
0.99 % |
of total Revenue |
| MEDTECH Orthopaedics KNEES International |
|
0.75 % |
of total Revenue |
| MEDTECH Orthopaedics TRAUMA |
|
3.46 % |
of total Revenue |
| MEDTECH Orthopaedics TRAUMA U S |
|
2.21 % |
of total Revenue |
| MEDTECH Orthopaedics TRAUMA International |
|
1.25 % |
of total Revenue |
| MEDTECH Orthopaedics SPINE OTHER |
|
2.88 % |
of total Revenue |
| MEDTECH Orthopaedics SPINE OTHER U S |
|
1.61 % |
of total Revenue |
| MEDTECH Orthopaedics SPINE OTHER International |
|
1.28 % |
of total Revenue |
| MEDTECH Surgery |
|
10.44 % |
of total Revenue |
| MEDTECH Surgery U S |
|
4.35 % |
of total Revenue |
| MEDTECH Surgery International |
|
6.09 % |
of total Revenue |
| MEDTECH Surgery ADVANCED |
|
4.67 % |
of total Revenue |
| MEDTECH Surgery ADVANCED U S |
|
1.98 % |
of total Revenue |
| MEDTECH Surgery ADVANCED International |
|
2.68 % |
of total Revenue |
| MEDTECH Surgery GENERAL |
|
5.77 % |
of total Revenue |
| MEDTECH Surgery GENERAL U S |
|
2.36 % |
of total Revenue |
| MEDTECH Surgery GENERAL International |
|
3.4 % |
of total Revenue |
| MEDTECH Vision |
|
5.67 % |
of total Revenue |
| MEDTECH Vision U S |
|
2.41 % |
of total Revenue |
| MEDTECH Vision International |
|
3.26 % |
of total Revenue |
| MEDTECH Vision CONTACT LENSES OTHER |
|
4.03 % |
of total Revenue |
| MEDTECH Vision CONTACT LENSES OTHER U S |
|
1.94 % |
of total Revenue |
| MEDTECH Vision CONTACT LENSES OTHER International |
|
2.08 % |
of total Revenue |
| MEDTECH Vision SURGICAL |
|
1.65 % |
of total Revenue |
| MEDTECH Vision SURGICAL U S |
|
0.46 % |
of total Revenue |
| MEDTECH Vision SURGICAL International |
|
1.18 % |
of total Revenue |
| United States |
|
55.4 % |
of total Revenue |
| Europe |
|
24.3 % |
of total Revenue |
| Western Hemisphere excluding U S |
|
5.37 % |
of total Revenue |
| Asia-Pacific Africa |
|
14.92 % |
of total Revenue |
